The impact of elexacaftor/tezacaftor/ivacaftor on cystic fibrosis health-related quality of life and decision-making about daily treatment regimens: a mixed methods exploratory study.

Melissa J BasileJennifer PoloKatherine HenthorneJoan DeCelie-GermanaSusan GalvinJanice Wang

Published in: Therapeutic advances in chronic disease (2024)

With little long-term data on the impact of reducing non-ETI treatments, participants weighed how they were feeling, treatment efficacy beliefs, and risk tolerance when making treatment decisions.

Keyphrases

cystic fibrosis
decision making
randomized controlled trial
chronic obstructive pulmonary disease
lung function
air pollution
electronic health record
deep learning
artificial intelligence
smoking cessation